Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029586 | 0.81 | GRM5 (0.51) | GRM5KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL31078384 | 0.81 | GRM5 (0.44) | GRM5KMT2AMEN1ALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL25307005 | 0.79 | GRM5 (0.43) | GRM5KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL2771743 | 0.78 | RAB9A (0.49) | GRM5KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL30070833 | 0.77 | KMT2A (0.72) | GRM5KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL2483314 | 0.77 | KMT2A (0.43) | L3MBTL1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL2483166 | 0.77 | KMT2A (0.72) | GRM5KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL14758347 | 0.77 | KMT2A (0.43) | L3MBTL1GRM5KMT2AMEN1CYP1A2 | |
| SCHEMBL1192307 | 0.74 | GRM5 (0.57) | GRM5KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL6176660 | 0.74 | KMT2A (0.41) | L3MBTL1GRM5KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1671969-A2 | Thiazolyl inhibitors of tec family tyrosine kinases | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7037926-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1347971-B1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060030598-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C | 2006-02-09 | — | — | US | disclosed |
| US-6958336-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-6956045-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-18 | — | — | US | disclosed |
| US-6953795-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-06-10 | — | — | US | disclosed |
| US-20040077695-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JO I C (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040067989-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | disclosed |
| US-6706717-B2 | ANTICANCER AGENTS; IMMUNOLOGY DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1347971-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-2002050071-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077695-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | L3MBTL1 1077/4885GRM5 4093/4885KMT2A 1071/4885 |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | L3MBTL1 1077/4885GRM5 4093/4885KMT2A 1071/4885 |
| US-20040067989-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | L3MBTL1 1077/4885GRM5 4093/4885KMT2A 1071/4885 |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | L3MBTL1 1077/4885GRM5 4093/4885KMT2A 1071/4885 |
| US-20060030598-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | L3MBTL1 1077/4885GRM5 4093/4885KMT2A 1071/4885 |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | L3MBTL1 1077/4885GRM5 4093/4885KMT2A 1071/4885 |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | L3MBTL1 2980/4885GRM5 13/4885KMT2A 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.